

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIV

In re application of:

MAY 2 5 2001

GERARD et al.

Art Unit: 1652

TECH CENTER 1600/2900

Appl. No.: 09/245,025

Examiner:

Filed: February 5, 1999

Atty. Docket: 0942.4330003/RWE/BJD

Tung, P.

For:

Compositions and Methods for Reverse Transcription of Nucleic

Acid Molecules



Reply to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or **Amino Acid Sequence Disclosures**

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Notice dated April 24, 2001 (Paper No. 12), requiring submission of a computer readable form of the Sequence Listing in the above-referenced patent application, Applicants hereby submit a copy of the PTO date-stamped postcard evidencing the filing of a Request to Open New Disk File concurrently with the captioned application on February 5, 1999, and resubmit a copy of the Utility Patent Application Transmittal, and the Request to Open New Disk File.

Applicants believe that the Notice was issued in error, and that the documents submitted herewith clearly evidence this oversight by the U.S. Patent and Trademark Office. Therefore, reconsideration and withdrawal of the Notice is respectfully requested.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are

GERARD *et al.* Appl. No. 09/245,025

- 2 -

necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036. A duplicate copy of this Reply is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants Registration No. 42,473

Date: May 23 200/

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005 (202) 371-2600

Due Date: N/A

Applicant:

GERARD et al.

Art Unit:

To be assigned:

Examiner:

Compositions and Methods for Reverse Transcription of Nucleic Acid Molecules

To be a

Application No.:

To be assigned (Divisional of U.S. Appl.

Docket:

No. 09/064,057)

Filed: Herewith

For:

Atty:

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Utility Patent Application Transmittal (Form PTO/SB/05); 2. Fee Transmittal (Form PTO/SB/17) (in duplicate); 3. U.S. Divisonal Patent Application entitled: Compositions and Methods for Reverse Transcription of Nucleic Acid Molecules and naming as inventors: Gary F. GERARD, Michael D. SMITH and Deb K. CHATTERJEE, the application consisting of: a. A specification containing: (i) 116 pages of description prior to the claims, including a sequence listing at pages 108-116; (ii) 16 pages of claims (115 claims); (iii) a one (1) page abstract; (iv) 54 sheets of drawings: (Figures 1-54); 4. Copy of the Declaration for Patent'Application, executed by the inventors in the parent application; 5. Preliminary Amendment; 6. Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate); 7. Request to Open New Disk File; 8. Our Check No. 23597 in the amount of \$1,120.00, to cover: \$760.00 utility filing fee; \$126.00 fee for excess total claims; and \$234.00 fee for excess independent claims; and 9. Two (2) return postcards.

PLEASE AFFIX RECEIPT DATE STAMP AND RETURN POSTCARD TO OUR COURIER

Box: Patent Application

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. GERARD First Inventor or Application UTILITY PATENT APPLICATION TRANSMITTAL Identifier Compositions and Methods for Reverse Transcription of (Only for new nonprovisional applications under 37 CFR § 1.53(b)) Nucleic Acid Molecules Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS Box Patent Application ADDRESS TO: See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 6. Microfiche Computer Program (Appendix) * Fee Transmittal Form (e.g., PTO/SB/17) 1. 🔯 (Submit an original, and a duplicate for fee processing) 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Total Pages 133 2. Specification (preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross References to Related Applications a. Computer Readable Copy Statement Regarding Fed sponsored R & D
Reference to Microfiche Appendix
Background of the Invention b. Paper Copy (identical to computer copy) Brief Summary of the Invention
Brief Description of the Drawings (If filed)
Detailed Description Statement verifying identity of above copies Claim(s) Abstract of the Disclosure ACCOMPANYING APPLICATION PARTS Drawing(s) (35 U.S.C. 113) 3. 🔯 8. Assignment Papers (cover sheet & document(s)) [Total Pages Oath or Declaration 4. 9. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignce) a. Newly executed (original or copy) English Translation Document (if applicable) b. Copy from a prior application (37 CFR 1.63(d)) (for Copies of IDS Citations ontinuation/divisional with Box 17 completed) [Note Box 5 below] Statement (IDS)/PTO-1449 Preliminary Amendment DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) 13. Return Receipt Postcard (MPEP 503) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). (Should be specifically itemized) Statement filed in prior *Small Entity Statement(s) @TO/SB/09-12) 14. application, Status still proper Incorporation By Reference (useable if Box 4b is checked) 5. 🔯 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by and desired 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) reference therein. 16. Other: 37 C.F.R. § 1.136(a)(3) Authorization Other: Request to Open New Disk File *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY FEES A SMALL ENTITY STATEMENT IS REQUIRED (37 C.FR § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.FR § 1.28). 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment: □Continuation-in-Part (CIP) of prior application No: <u>09/064,057</u> ☑ Divisional ☐ Continuation Group/Art Unit: 1634 Prior application information: Examiner Whisenant, E. 18. CORRESPONDENCE ADDRESS or Correspondence Customer Number address below (Insert Customer No. or Attach bar code label here) or Bar Code Label STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. NAMB Attorneys at Law Suite 600, 1100 New York Avenue, N.W. ADDRESS 20005-3934 ZIP CODE DC STATE Washington CITY (202) 371-2540 **FAX** (202) 371-2600 TELEPHONE COUNTRY USA Registration No. (Attorney/Agent) 42.473 Brian J. Del Buono NAME (Print/Type)

Date Hebray 5, 1999 RIZUSTOVO SIGNATURE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERARD et al.

Appl. No. (To be assigned; Divisional of U.S. Appl. No. 09/064,057)

Filed: (Herewith)

For:

Compositions and Methods for Reverse Transcription of Nucleic

Acid Molecules

Art Unit:

(To be assigned)

Examiner:

(To be assigned)

Atty. Docket: 0942.4330003/RWE/BJD

Request to Open New Disk File

Assistant Commissioner for Patents Washington, D.C. 20231

Applicants request that a new disk file be opened for the above-cited application. The Sir: Sequence Listing disk submitted on April 22, 1998, in the parent, U.S. Application No. 09/064,057, filed April 22, 1998, contains the identical sequence information as that in the present application.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Agent for Applicants Registration No. 42,473

Brantolli

Date: Jebnay 5, 1999

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

P:\USERS\BRIAND\0942\4330003\020599.seq.lst.req SKGF Rev.1/27/98 dcw

Applicati	No.:_	09/ 245,025	
-----------	-------	-------------	--

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

Applicant Must Provide:

 $\overline{\chi}$ An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY